In one study, the combination of EGFR-TKIs and cetuximab completely depleted phosphorylated and total EGFR in mice suffering from L8s8R/T790M erlotinib resistance, causing near-complete tumor regression (63). The gene discussed is EGFR; the disease is neoplasm.